CoChat

Transient Immunomodulation Allows Repeated Injections of AAV1 and Correction of Muscular Dystrophy in Multiple Muscles

Open access

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Abstract

Exon-skipping AAV1-U7-associated therapy is a promising treatment for Duchenne muscular dystrophy (DMD). We have shown earlier that the newly rescued dystrophin protein is stably expressed for months in mice and dogs, and does not induce immune rejection of transduced fibers. In this study, we used the dystrophic mdx mouse as a preclinical model to characterize the immune response to the adeno-associated virus 1 (AAV1) vector, and tested the feasibility of administering multiple AAV1 injections to extend the treatment to several muscles. We found that re-injections of AAV1 vector are compromised as early as 3 days after the first injection, coincident with a rapid increase in AAV1-specific immunoglobulin M (IgM) and IgG in the serum. Adoptive transfer of immune sera confirmed the rapid appearance of an AAV1 neutralization activity, and experiments with immunoglobulin-deficient (microKO) mice proved that antibodies (Abs) are the only effectors responsible for AAV1-U7 elimination. It is important to note, however, that the AAV2 vector still generated an adverse immune response in microKO mice. By blocking the T-B crosstalk with anti-CD40 Abs and CTLA4/Fc fusion protein, we found that a mere 5 days of immunomodulation treatment was sufficient to totally abrogate the formation of anti-AAV1 Abs and to allow for the correction of muscular dystrophy in multiple muscles, provided the treatment was administered during each challenge.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.mt.6300377

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 67

Metadata

Authors
Lorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L.
Affiliations
  • Inserm (FR)
  • Hôpital Necker-Enfants Malades (FR)
  • University of Oxford (GB)
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2008-03
Volume
16
Issue
3
Pages
541-547
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2005245653
Cited by
62
References
46
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 4
FWCI
1.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Centre National de la Recherche Scientifique
  • Duchenne Parent Project
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
Duchenne muscular dystrophy, AAV1, exon skipping, mdx mice, adoptive transfer, AAV2, immunomodulation, gene therapy
MeSH terms
Abatacept, Dependovirus, Animals, Antibody Formation, Fluorescent Antibody Technique, Genetic Vectors, Immunoglobulin G, Immunoglobulin M, Immunoglobulins, Mice, Inbred C57BL, Transduction, Genetic, Genetic Therapy, Immunoconjugates, CD40 Antigens, Muscular Dystrophy, Duchenne, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transient Immunomodulation Allows Repeated Injections of AAV1 and Correction of Muscular Dystrophy in Multiple Muscles. https://app.cochat.ai/papers/10.1038/sj.mt.6300377
The paper
Lorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L. (2008). Transient Immunomodulation Allows Repeated Injections of AAV1 and Correction of Muscular Dystrophy in Multiple Muscles. Molecular Therapy. https://doi.org/10.1038/sj.mt.6300377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.